Trazodone for Sleep Disorders in Alzheimer's Disease

Last updated: October 12, 2012
Sponsor: Brasilia University Hospital
Overall Status: Completed

Phase

3

Condition

Sleep Disorders

Alzheimer's Disease

Dementia

Treatment

N/A

Clinical Study ID

NCT01142258
TZD-001
  • Ages > 55
  • All Genders

Study Summary

The purpose of this study is to determine whether trazodone is effective in the treatment of sleep disorders in Alzheimer's disease (AD).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Fifty-five years of age or older;

  • Diagnosis of probable Alzheimer's disease by National Institute of Neurological andCommunicative Disorders and Stroke/the Alzheimer's Disease and Related DisordersAssociation criteria;

  • Hachinski Ischemia Scale score less than 5

  • Mini-Mental State Examination score of O to 26

  • Actigraph evidence of a mean time immobile of less than 7 hours per night based on atleast 7 nights of complete actigraph data collected over a single week;

  • For-week history of sleep disorder behaviors, occurring at least once weekly, asreported by the caregiver using the Neuropsychiatric Inventory (NPI) NighttimeBehavior scale;

  • Sleep disturbance observed was not present before the diagnosis of AD;

  • Other co-morbidities, especially delirium, depression, chronic pain and medication usemay be present, but do not cooperate in the primary symptoms;

  • Computed tomography or magnetic resonance imaging since the onset of memory problemsshowing no more than 1 lacunar infarct in a nonstrategic area and no clinical eventssuggestive of stroke or other intracranial disease or normal;

  • Stable medications for 4 weeks prior to the screening visit;

  • Having a mobile upper extremity to which to attach an actigraph;

  • Residing with a responsible spouse, family member, or professional caregiver who ispresent during the night and would agree to assume the role of the principal caregiverfor the 3-week protocol;

  • Ability to ingest oral medication and participate in all scheduled evaluations

Exclusion

Exclusion Criteria:

  • Sleep disturbance associated with an acute illness, delirium or psychiatric disease;

  • Clinically significant movement disorder, such as akinesia, that would affectactigraphic differentiation of sleep and wakefulness

  • Severe agitation;

  • Unstable medical condition;

  • Discontinuation of psychotropic or sleep medications within 2 weeks of the screeningvisit;

  • Patient unwilling to maintain caffeine abstinence after 2:00 PM for the duration ofthe protocol;

  • Patient unwilling to comply with the maximum limit of 2 alcoholic drinks per day, andonly 1 alcoholic drink after 6:00 PM for the duration of the protocol;

  • Prior use of trazodone for the treatment of sleep disturbances;

  • Caregiver deemed too unreliable to supervise the wearing of the actigraph, toadminister trazodone the proper time, to maintain tbe sleep diary, or to bring thepatient to the scheduled visits;

Study Design

Total Participants: 40
Study Start date:
March 01, 2010
Estimated Completion Date:
August 31, 2012

Study Description

Sleep disorders (SD) affects 35 to 50 percent of patients with AD. These disorders often make caring for patients at home very difficult. Trazodone is commonly prescribed drugs for SD in AD patients. There are no controlled studies in this sample of patients for this purpose.

Connect with a study center

  • Geriatric Medical Centre

    Brasilia, Distrito Federal
    Brazil

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.